drugset / Trial / NCT02172443

Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease

NCT02172443

Phase 3 Completed 50 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to compare the bronchodilator efficacy and safety of tiotropium inhalation capsule (18 mcg once daily) and Atrovent MDI (2 puffs of 20 mcg q.i.d.) in patients with chronic obstructive pulmonary disease (COPD)

Timeline

Start
2001-06
Primary completion
2002-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ipratropium Small molecule 20 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled